Abstract:Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI- TOF- MS is a potential tool for the screening of lung cancer.

Discovery of Serum Biomarkers in Astrocytoma by SELDI–TOF MS and Proteinchip Technology

Proteomic Diagnosis Models from Serum for Early Detection of Oral Squamous Cell Carcinoma.

Diagnosis of pancreatic adenocarcinoma using protein chip technology.

Serum Protein Fingerprinting Coupled with Artificial Neural Network Distinguishes Glioma from Healthy Population or Brain Benign Tumor

Mass Spectrometric Analysis of Cerebrospinal Fluid Protein for Glioma and Its Clinical Application

Fingerprint pattern analysis of glioma CSF protein with mass spectrometry and its clinical significance

Establishment of Diagnostic Model of Cerebrospinal Protein Fingerprint Pattern for Glioma and Its Clinical Application

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population and brain benign tumo

Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics

New Serum Biomarkers For Early Diagnosis Of Prostate Cancer Using Seldi Protein Chip Technology

Screening Glioma’s Disease-Related Proteins in Serum

Identification of Seven Serum Micrornas from a Genome‐wide Serum Microrna Expression Profile As Potential Noninvasive Biomarkers for Malignant Astrocytomas

Application of Serum Seldi Proteomic Patterns in Diagnosis of Lung Cancer

SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.

Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Gliomas.

Differential Expression of Proteomics Models of Colorectal Cancer, Colorectal Benign Disease and Healthy Controls

Proteomic Approaches to Biomarker Discovery in Lung Cancers by SELDI Technology

[Establishment of serum protein pattern model for screening pancreatic cancers by SELDI-TOF-MS technique]

Use of SELDI-TOF-MS method to identify patients with osteosarcoma

Clinical Significance of Biomarkers from Serum in Liver Cancer by SELDI-TOF Mass Spectrometry

Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches